Participants must be on a stable dose of all background LLTs
The stable statin dose should be judged as their maximally tolerated dose
Participants should have either history of a clinical ASCVD event or be at increased risk for a first clinical ASCVD event
You may not be if
Asian origin
Uncontrolled severe hypertension
Uncontrolled T2DM
Inadequately treated hypothyroidism
Clareo Health | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
